Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.47 |
| ▸ | PPARG | P37231 | 15/20 | 0.47 |
| ▸ | PPARD | Q03181 | 15/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17540651 | 1.00 | PPARA (0.47) | PPARAPPARGPPARDGAASMN1; SMN2 | |
| SCHEMBL17540666 | 1.00 | PPARA (0.47) | PPARAPPARGPPARDGAASMN1; SMN2 | |
| SCHEMBL17792278 | 0.91 | PPARA (0.46) | PPARAPPARGPPARD | |
| SCHEMBL17792273 | 0.91 | PPARA (0.46) | PPARAPPARGPPARD | |
| SCHEMBL17540676 | 0.91 | PPARA (0.59) | PPARAPPARGPPARD | |
| SCHEMBL17540655 | 0.91 | PPARA (0.59) | PPARAPPARGPPARD | |
| SCHEMBL17540662 | 0.91 | PPARA (0.59) | PPARAPPARGPPARD | |
| SCHEMBL17540650 | 0.91 | PPARA (0.59) | PPARAPPARGPPARD | |
| SCHEMBL14479947 | 0.89 | NPC1 (0.57) | PPARAPPARGPPARDSMN1; SMN2TDP1 | |
| SCHEMBL14479989 | 0.89 | NPC1 (0.57) | PPARAPPARGPPARDSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARA 3/4885PPARG 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.